Aligos Therapeutics, Inc. Operating Lease Cost
Aligos Therapeutics, Inc. (ALGS) reported Operating Lease Cost of $2.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-05
- Aligos Therapeutics, Inc. operating lease, cost for the quarter ending 2021-12-31 was $493.00K, a 9.56% increase year-over-year.
- Aligos Therapeutics, Inc. operating lease, cost for the quarter ending 2021-09-30 was $505.00K, a 8.84% increase year-over-year.
- Aligos Therapeutics, Inc. operating lease, cost for the quarter ending 2021-06-30 was $484.00K, a 2.54% increase year-over-year.
- Aligos Therapeutics, Inc. operating lease, cost for the quarter ending 2021-03-31 was $469.00K, a 1.52% increase year-over-year.
- Aligos Therapeutics, Inc. operating lease, cost for fiscal 2025 was $2.46M, a 27.50% increase from fiscal 2024.
- Aligos Therapeutics, Inc. operating lease, cost for fiscal 2024 was $1.93M, a 16.80% decline from fiscal 2023.
- Aligos Therapeutics, Inc. operating lease, cost for fiscal 2023 was $2.32M, a 7.31% decline from fiscal 2022.
- Aligos Therapeutics, Inc. operating lease, cost for fiscal 2022 was $2.50M, a 25.83% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.46M 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $1.93M 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $2.32M 10-K · filed 2025-03-10 | |||
| 2022-12-31 | $2.50M 10-K · filed 2024-03-12 | |||
| 2021-12-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $998.00K derived: sum of 2 quarters · filed 2023-03-09 | $1.48M derived: sum of 3 quarters · filed 2023-03-09 | $1.99M 10-K · filed 2023-03-09 |
| 2021-09-30 | $505.00K 10-Q · filed 2021-11-04 | $989.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.50M 10-Q · filed 2021-11-04 | $1.91M derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-06-30 | $484.00K 10-Q · filed 2021-08-05 | $953.00K 10-Q · filed 2021-08-05 | $1.40M derived: sum of 3 quarters · filed 2022-03-10 | $1.87M derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-03-31 | $469.00K 10-Q · filed 2021-05-10 | $919.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.38M derived: sum of 3 quarters · filed 2022-03-10 | $1.85M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $914.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.39M derived: sum of 3 quarters · filed 2022-03-10 | $1.85M 10-K · filed 2022-03-10 |
| 2020-09-30 | $464.00K 10-Q · filed 2021-11-04 | $936.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.40M 10-Q · filed 2021-11-04 | $1.85M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $472.00K 10-Q · filed 2021-08-05 | $934.00K 10-Q · filed 2021-08-05 | $1.39M derived: sum of 3 quarters · filed 2021-08-05 | $1.96M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $462.00K 10-Q · filed 2021-05-10 | $916.00K derived: sum of 2 quarters · filed 2021-05-10 | $1.48M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $1.02M derived: sum of 2 quarters · filed 2021-03-23 | $2.23M 10-K · filed 2021-03-23 | |
| 2019-09-30 | $568.00K 10-Q · filed 2020-11-25 | $1.77M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |